Brentuximab vedotin (Adcetris®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000847
English
Authors' recommendations:
Brentuximab vedotin (Adcetris®) is recommended for restricted use within NHS Wales for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Brentuximab vedotin (Adcetris®) is not recommended for use within NHS Wales for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1255
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Brentuximab Vedotin
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Lymphoma
- Hodgkin Disease
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.